| Dr Bernard Joseph Durante, MD | |
|
30 Aldrin Road, Plymouth, MA 02360 | |
| (508) 746-8977 | |
| (508) 746-3364 |
| Full Name | Dr Bernard Joseph Durante |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 42 Years |
| Location | 30 Aldrin Road, Plymouth, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164400040 | NPI | - | NPPES |
| 3022811 | Medicaid | MA | |
| 19073 | Other | MA | HARVARD PILGRIM HEALTH |
| 2652138 | Other | MA | AETNA |
| 043585201 | Other | MA | HEALTHCAREVALUEMANAGEMENT |
| 040016605 | Other | MA | RAILROAD MEDICARE |
| 711390 | Other | MA | TUFTS HEALTH PLAN |
| B20014301 | Other | MA | CIGNA |
| J06669 | Other | MA | BLUECROSSBLUESHIELD |
| 1000029 | Other | MA | UNITED HEALTHCARE |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beth Israel Deaconess Hospital Plymouth | Plymouth, MA | Hospital |
| Cape Cod Healthcare | Hyannis, MA | Hospital |
| Falmouth Hospital | Falmouth, MA | Hospital |
| Southcoast Hospitals Group | Fall river, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bernard J Durante Md Pc | 3577539410 | 11 |
News Archive
Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity in individuals with a genetic deficiency in the MC4R pathway.
The United States Pharmacopeia (USP) has released free documentary standards for medicines used outside the United States to treat neglected infectious diseases.
The Washington state House Health Care and Wellness Committee on Wednesday recommended approval of a bill (HB 1071) that would expand a state health insurance program to include undocumented immigrant children, the Spokane Spokesman-Review reports.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
Malignant tumours often spread to remote areas of the body. In the majority of cases, metastases formation develops via the blood vascular system. The blood platelets thereby provide invaluable help to the tumour cells in penetrating new organs.
› Verified 9 days ago
| Entity Name | Jordan Physician Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538145131 PECOS PAC ID: 1254321086 Enrollment ID: O20040514000167 |
News Archive
Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity in individuals with a genetic deficiency in the MC4R pathway.
The United States Pharmacopeia (USP) has released free documentary standards for medicines used outside the United States to treat neglected infectious diseases.
The Washington state House Health Care and Wellness Committee on Wednesday recommended approval of a bill (HB 1071) that would expand a state health insurance program to include undocumented immigrant children, the Spokane Spokesman-Review reports.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
Malignant tumours often spread to remote areas of the body. In the majority of cases, metastases formation develops via the blood vascular system. The blood platelets thereby provide invaluable help to the tumour cells in penetrating new organs.
› Verified 9 days ago
| Entity Name | Bernard J Durante Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114024312 PECOS PAC ID: 3577539410 Enrollment ID: O20040902000665 |
News Archive
Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity in individuals with a genetic deficiency in the MC4R pathway.
The United States Pharmacopeia (USP) has released free documentary standards for medicines used outside the United States to treat neglected infectious diseases.
The Washington state House Health Care and Wellness Committee on Wednesday recommended approval of a bill (HB 1071) that would expand a state health insurance program to include undocumented immigrant children, the Spokane Spokesman-Review reports.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
Malignant tumours often spread to remote areas of the body. In the majority of cases, metastases formation develops via the blood vascular system. The blood platelets thereby provide invaluable help to the tumour cells in penetrating new organs.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bernard Joseph Durante, MD 30 Aldrin Road, Plymouth, MA 02360 Ph: (508) 746-8977 | Dr Bernard Joseph Durante, MD 30 Aldrin Road, Plymouth, MA 02360 Ph: (508) 746-8977 |
News Archive
Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity in individuals with a genetic deficiency in the MC4R pathway.
The United States Pharmacopeia (USP) has released free documentary standards for medicines used outside the United States to treat neglected infectious diseases.
The Washington state House Health Care and Wellness Committee on Wednesday recommended approval of a bill (HB 1071) that would expand a state health insurance program to include undocumented immigrant children, the Spokane Spokesman-Review reports.
Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.
Malignant tumours often spread to remote areas of the body. In the majority of cases, metastases formation develops via the blood vascular system. The blood platelets thereby provide invaluable help to the tumour cells in penetrating new organs.
› Verified 9 days ago